Top-News

CALLIDITAS THERAP. AD 1/2 News

Aktie
WKN:  A2P57K ISIN:  US13124Q1067 US-Symbol:  CALT
39,99 $
+1,01 $
+2,59%
31.05.24 21:59:11
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-

CALLIDITAS THERAP. AD 1/2 News

30.05.24 - PR Newswire
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy PR Newswire
30.05.24 - PR Newswire
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy PR Newswire
29.05.24 - PR Newswire
SHAREHOLDER ALERT: Halper Sadeh LLC Continues to Investigate SRDX, MRO, ATRI, CALT
SHAREHOLDER ALERT: Halper Sadeh LLC Continues to Investigate SRDX, MRO, ATRI, CALT PR Newswire
28.05.24 - PR Newswire
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress PR Newswire
28.05.24 - PR Newswire
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress PR Newswire
28.05.24 - PR Newswire
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation PR Newswire
28.05.24 - PR Newswire
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation PR Newswire
23.05.24 - PR Newswire
Calliditas Q1 report, January - March 2024
Calliditas Q1 report, January - March 2024 PR Newswire
23.05.24 - PR Newswire
Calliditas Q1 report, January - March 2024
Calliditas Q1 report, January - March 2024 PR Newswire
16.05.24 - PR Newswire
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
In-Person & Virtual R&D Day: The Anti-​Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action PR Newswire
16.05.24 - PR Newswire
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
In-Person & Virtual R&D Day: The Anti-​Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action PR Newswire
16.05.24 - PR Newswire
Invitation to the presentation of Calliditas´s interim report January - March 2024
Invitation to the presentation of Calliditas´s interim report January - March 2024 PR Newswire
16.05.24 - PR Newswire
Invitation to the presentation of Calliditas´s interim report January - March 2024
Invitation to the presentation of Calliditas´s interim report January - March 2024 PR Newswire
15.05.24 - PR Newswire
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm PR Newswire
15.05.24 - PR Newswire
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm PR Newswire
15.05.24 - PR Newswire
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
Notice of annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire
15.05.24 - PR Newswire
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
Notice of annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire
14.05.24 - PR Newswire
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China PR Newswire
14.05.24 - PR Newswire
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China PR Newswire
06.05.24 - PR Newswire
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR Newswire

Newssuche

Videos

newspaper
29.05.24 +31,94%
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »